Spruce Biosciences (SPRB) Current Assets (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Current Assets of $55.0 million for Q1 2026, up 79.98% year-over-year from $30.6 million in Q1 2025, and up 5.6% quarter-over-quarter from $52.1 million in Q4 2025.
Spruce Biosciences (SPRB) Current Assets (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Current Assets for 8 consecutive years, with $55.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 79.98% year-over-year to $55.0 million; the TTM figure through Mar 2026 stood at $55.0 million (up 79.98% YoY), while the FY2025 annual figure was $52.1 million, up 17.88% from the prior year.
- Current Assets grew to $55.0 million in Q1 2026 per SPRB's latest filing, from $52.1 million in the prior quarter.
- Across five years, Current Assets topped out at $137.2 million in Q1 2023 and bottomed at $14.5 million in Q3 2025.
- Historically, Current Assets has averaged $75.5 million across 5 years, with a median of $83.6 million in 2022.
- Annual changes were most pronounced in 2025 — Current Assets sank 77.17% — and 2026, when it soared 79.98%.
- Spruce Biosciences' Current Assets stood at $83.6 million in 2022, then rose by 22.22% to $102.2 million in 2023, then plunged by 56.74% to $44.2 million in 2024, then increased by 17.88% to $52.1 million in 2025, then advanced by 5.6% to $55.0 million in 2026.
- Business Quant data shows SPRB's Current Assets at $55.0 million in Q1 2026, $52.1 million in Q4 2025, and $14.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.69 Bn | 130.84 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.29 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.79 Bn | 59.60 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.44 Bn | 54.31 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.92 Bn | 27.61 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.10 Bn | 9.71 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.33 Bn | 26.17 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 1.76 Bn |
| 10 | Spruce Biosciences | 127.00 Mn | 127.00 Mn | - | 101.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 101.15 Mn |
| Mar 31, 2026 | 55.03 Mn |
| Dec 31, 2025 | 52.11 Mn |
| Sep 30, 2025 | 14.52 Mn |
| Jun 30, 2025 | 20.95 Mn |
| Mar 31, 2025 | 30.58 Mn |
| Dec 31, 2024 | 44.21 Mn |
| Sep 30, 2024 | 63.57 Mn |
| Jun 30, 2024 | 73.91 Mn |
| Mar 31, 2024 | 85.87 Mn |
| Dec 31, 2023 | 102.18 Mn |
| Sep 30, 2023 | 111.14 Mn |
| Jun 30, 2023 | 124.13 Mn |
| Mar 31, 2023 | 137.24 Mn |
| Dec 31, 2022 | 83.61 Mn |
| Sep 30, 2022 | 93.19 Mn |
| Jun 30, 2022 | 96.51 Mn |
| Mar 31, 2022 | 95.10 Mn |
| Dec 31, 2021 | 91.90 Mn |
| Sep 30, 2021 | 93.92 Mn |